

(19)

Europäisches Patentamt
European Patent Office
Office européen des brevets



(11)

EP 0 627 218 B1

(12)

EUROPEAN PATENT SPECIFICATION

(45) Date of publication and mention
of the grant of the patent:
19.12.2001 Bulletin 2001/51

(51) Int Cl.7: **A61K 9/20**, A61K 47/10,
A61K 47/26, A61K 9/00

(21) Application number: **93904312.1**

(86) International application number:
PCT/JP93/00192

(22) Date of filing: **17.02.1993**

(87) International publication number:
WO 93/15724 (19.08.1993 Gazette 1993/20)

(54) **Process for producing fast soluble tablets and fast soluble tablets comprising xylitol**

Verfahren zur Herstellung von schnelllöslicher Tabletten und schnelllöslichen Tablette beinhaltend
Xylitol

Procédé de preparation de tablettes à dissolution rapide et tablettes solubles rapidement comprenant
xylitol

(84) Designated Contracting States:
**AT BE CH DE DK ES FR GB GR IE IT LI LU MC NL
PT SE**

(30) Priority: **18.02.1992 JP 6956592**

(43) Date of publication of application:
07.12.1994 Bulletin 1994/49

(73) Proprietor: **NIPPON SHINYAKU COMPANY,
LIMITED**
Minami-ku Kyoto-shi Kyoto 601 (JP)

(72) Inventors:
• **NAKAMICHI, Kouichi**
Koga-gun, Shiga 520-32 (JP)

• **IZUMI, Shogo**
Kameoka-shi, Kyoto 621 (JP)
• **YASUURA, Hiroyuki**
Kusatsu-shi, Shiga 525 (JP)

(74) Representative: **Hillier, Peter et al**
Edward Evans Barker Clifford's Inn Fetter Lane
London EC4A 1BZ (GB)

(56) References cited:
EP-A- 0 371 466 **JP-A- 53 044 618**
JP-A- 60 255 736 **JP-A- 61 205 208**

EP 0 627 218 B1

Note: Within nine months from the publication of the mention of the grant of the European patent, any person may give notice to the European Patent Office of opposition to the European patent granted. Notice of opposition shall be filed in a written reasoned statement. It shall not be deemed to have been filed until the opposition fee has been paid. (Art. 99(1) European Patent Convention).

Description

- [0001] The present invention relates to a drug-containing fast soluble tablet that dissolves rapidly in the oral cavity.
- [0002] The fast soluble tablet usually dissolves in the oral cavity within 15 seconds to 3 minutes, and is suitable for administration to infants, the aged, severely affected patients and others who have difficulty in taking tablets.
- [0003] Oral dosage forms of drugs include tablets, granules, powders and liquids. Liquids, such as syrups, are suitable for administration to the physically weakened aged and infants because they are easily swallowable. However, they are not convenient because they must be accurately weighed for each use. Another drawback is that the tendency to deteriorate easily upon exposure to heat or atmosphere degrades the drug's chemical and physical stability.
- [0004] Granules and powders are free of the above drawbacks, but they are not easily swallowable, and taking the accurate dose is difficult unless they are taken with water etc.
- [0005] Tablets are suitable for administration of a certain accurate volumes and offers excellent chemical and physical stability for the drug contained, but they have a drawback of difficult swallow for infants, the aged, severely affected patients and others. Overcoming the drawback of poor swallowability would make it possible to provide an excellent preparation free of the above-described drawbacks in other dosage forms.
- [0006] As a solution to the problem of poor swallowability in tablets, freeze-dried preparations in a tablet form, based on a water-soluble polymer, have recently been developed (e.g., Japanese Patent Unexamined Publication Nos. 44619/1978 and 86837/1991). They have overcome the drawback of poor swallowability in tablets by causing the preparation to dissolve rapidly in the oral cavity. However, they require a special preparation technology known as freeze-drying, resulting in drawbacks such as difficulty in industrial mass-production, high production cost and poor physical stability.
- [0007] In recent years, tablets have been produced by subjecting tablet components to compressive shaping under high pressure in a dry state. This is because tablets are essentially intended to be disintegrated in the gastrointestinal tract to cause drug absorption and must be physically and chemically stable from completion of tableting to reach to the gastrointestinal tract, so that the tablet components must be strongly bound together by a compressive pressure. In early times, wet tablets were available, which were molded and shaped into tablets while in a wet state, followed by drying. However, such tablets were not rapidly soluble in the oral cavity because they were intended to be disintegrated in the gastrointestinal tract. Also, as these tablets are not strongly compressed mechanically and lack shape retention, they are not practically applicable to modern use.
- [0008] EP-A1-0371466 discloses a fast dissolving buccal tablet for administering a medicament which includes the active ingredient, a lubricant and a water soluble sugar, such as sorbitol, combined such that the buccal tablet dissolves in about one minute.
- [0009] Patent Abstracts of Japan 1256 C78, No. 53-44618 discloses the preparation of a disintegratable, easily administrable small-sized tablet with high productivity, by mixing granules obtained by the wet-granulation of propionic acid maridomycins with a specific binder, and adjusting the water-content to 4-8%.
- [0010] The object of the present invention is to provide a method of producing a fast soluble tablet by a simple method without the above-described special preparation technology known as freeze-drying.
- [0011] Accordingly, the invention provides a process for producing pharmaceutical tablets and a tablet as claimed in claims 1 and 7 respectively.
- [0012] Through intensive investigation, the present inventors found that the above object could be accomplished by producing tablets based on a pharmaceutical additive rapidly soluble in water by a modification of the conventional tableting method based on wet granulation and completed the present invention.
- [0013] A gist of the present invention is characterized by two features: 1) the tablet base component is a pharmaceutical additive rapidly soluble in water, and 2) a kneaded mixture of a drug and a pharmaceutical additive rapidly soluble in water is subjected to compressive shaping while in a wet state.
- [0014] The present invention is hereinafter described in detail. In the method of the present invention the pharmaceutical additive rapidly soluble in water may be any water-soluble crystalline or powdery solid, exemplified by substances in common use as excipients. It is preferable, however, that the pharmaceutical additive is a sweetening substance, since the fast soluble tablet of the present invention dissolves rapidly in the oral cavity. Such substances include saccharides such as sucrose, lactose, glucose and fructose, and sugar alcohols such as xylitol, sorbitol and mannitol.
- [0015] Of the above-mentioned sugar alcohols, xylitol is preferred because it has a good taste and dissolves most rapidly in the oral cavity. Mannitol and lactose are excellent in the compressive property described later, although they are inferior to xylitol in taste and dissolution rate.
- [0016] In the present invention, these substances may be used in combination. Appropriate combination can offer only a combination of advantages thereof.
- [0017] The fast soluble tablet relating to the present invention is produced by subjecting a kneaded mixture of a pharmaceutical additive rapidly soluble in water as described above and a drug to compressive shaping before drying when compressive shaping is performed in the conventional tableting method based on wet granulation. The present

tablets are different from conventional tablets in that the shaping and drying operations are reversed in order; conventional tablets are produced by mixing starting materials, adding a binder, kneading and drying the mixture and subjecting the mixture to compressive shaping.

[0018] The compressive shaping pressure for shaping the fast soluble tablet relating to the present invention may be relatively low, e.g., 490 - 9800 N (50 - 1,000 kg) is sufficient. Although decreasing the pressure tends to yield tablets of shorter oral cavity dissolution time, compressive shaping pressures lower than 490 N (50 kg) result in formation of practically unapplicable tablets with insufficient tensile strength. Although increasing the pressure tends to yield more tough tablets of improved tensile strength, compressive shaping pressures exceeding 9800 N (1,000 kg) usually result in formation of tablets of longer oral cavity dissolution time. In some cases, however, tablets with practically acceptable strength are obtained from an appropriate combination of two or more the pharmaceutical additives, even when the compressive shaping pressure is lower than 490 N (50 kg). Also, in some cases tablets with shorter oral cavity dissolution time may be obtained from an appropriate combination of two or more the pharmaceutical additives, even when the compressive shaping pressure exceeds 9800 N (1,000 kg). Fast soluble tablets produced under a compressive shaping pressure out of the range of 490 - 9800 N (50 - 1,000 kg) are therefore included in the scope of the present invention.

[0019] Tablets whose tensile strength exceeds 49×10^4 Pa (5 kg/cm²) are practically applicable. In some cases, however, tablets with even lower tensile strength are practically applicable if they are packaged in suitable forms.

[0020] The mechanical strength of the fast soluble tablet relating to the present invention is retained mainly by the crosslinking force of the pharmaceutical additive rapidly soluble in water.

[0021] Conventional tablets are produced under compressive shaping pressures of about 9800 - 29400 N (500 - 3,000 kg).

[0022] When a sugar alcohol is applied in the present invention, e.g., xylitol is used alone, it is preferable that the compressive shaping pressure is about 490 - 2940 N (50 - 300 kg). Lower compressive shaping pressures make tablet shaping difficult. Higher compressive shaping pressures result in formation of practically unapplicable tablets of insufficient tensile strength (see Figure 1).

[0023] When xylitol alone is used as a sugar alcohol, compressive shaping pressures exceeding 2940 N (300 kg) result in formation of tablets with decreased tensile strength and increased oral cavity dissolution time. When xylitol is used in a mixture with lactose, mannitol or the like, tablets with sufficiently high tensile strength and short oral cavity dissolution time can be obtained even when the compressive shaping pressure exceeds 2940 N (300 kg).

[0024] For example, when xylitol is used in combination with lactose, tablets with shorter oral cavity dissolution time and sufficient tensile strength can be obtained by mixing them in a ratio of, for example, 8:2 (see Figure 2).

[0025] For example, when xylitol is used in combination with mannitol, tablets with shorter oral cavity dissolution time and sufficient tensile strength can be obtained by mixing them in a ratio of, for example, 8:2 (see Figure 3).

[0026] As mentioned above, when xylitol is used in a mixture with lactose or mannitol, better results are obtained than those obtained with xylitol alone. These results, however, have not been expected from the results with mannitol alone or lactose alone. This is because using mannitol alone or lactose alone results in considerably increased oral cavity dissolution time as well as increased tensile strength when the compressive shaping pressure exceeds 2940 N (300 kg) (see Figure 4).

[0027] The fast soluble tablet relating to the present invention displays rapid dissolution in the oral cavity. For example, when it is intended to incorporate a drug which may cause a problem, if used as such, e.g., a drug which has a high bitterness, a masking treatment such as microcapsulation or crystal surface coating is performed as appropriate, after which the drug is incorporated in the fast soluble tablet of the present invention, result in elimination of such problem.

[0028] The kneaded mixture of a drug and a pharmaceutical additive rapidly soluble in water is usually prepared by mixing the pharmaceutical additive rapidly soluble in water and the appropriately treated drug, adding and uniformly dispersing water, a binder solution or a saturated sugar solution, and kneading. The amount of water added is preferably about 1 - 10% by weight, most preferably about 3% by weight, in the tablet composition before compressive shaping. Excess water results in dissolution of sugar alcohol or sugar, or decreased shape retention, which in turn adversely affect the compressive shaping that follows and make it difficult to dry the shaped product. Insufficient water results in tableting failures such as cracking at shaping, thus hampering preferred embodiment. The shaped tablet, even if obtained, lacks mechanical strength, and is fragile. The water added is preferably purified water, for instance.

[0029] Compressive shaping can be achieved, irrespective of the form of the kneaded mixture, whether particulate, granular, soft lumpy or the like, as long as the kneaded mixture of the drug and the pharmaceutical additive rapidly soluble in water is wet. Compressive shaping machines which can be used include ordinary tableting machines, automatic compressive shaping machines for Japanese cakes and lump sugar machines.

[0030] The fast soluble tablet relating to the present invention can be produced more simply and in larger amounts, in comparison with the above-described tableting method using freeze-drying technique, because they can be produced by a modification of the conventional tableting method based on wet granulation compression, as stated above.

[0031] In the present invention, to further improve the physical properties of the preparation, known binders may be

added in the process of the kneading operation. Although the binder for the present invention is not subject to limitation, preference is given to substances of relatively high dissolution rate. Such binders include polyvinylpyrrolidone (PVP), hydroxypropyl cellulose (HPC) and hydroxypropyl methylcellulose (HPMC) and the like. Acacia etc. may also be incorporated as appropriate.

- 5 [0032] The binder for the present invention may be contained at 0.1 to several percent by weight, preferably about 0.5 - 1% by weight, in the tablet composition before compressive shaping.

[0033] The fast soluble tablet relating to the present invention may be glazed by steam exposure for one to several seconds after compressive shaping and drying, to smooth the tablet surface for good appearance and prevent abrasion of the tablet surface.

- 10 [0034] Any drug is applicable to the fast soluble tablet relating to the present invention, as long as it is orally administered. Such drugs include the following:

1. Antipyretic analgesic anti-inflammatory agents

- 15 Indomethacin, aspirin, diclofenac sodium, ketoprofen, ibuprofen, mefenamic acid, dexamethasone, dexamethasone sodium sulfate, hydrocortisone, prednisolone, azulene, phenacetin, isopropylantipyrin, acetaminophen, benzydamine hydrochloride, phenylbutazone, flufenamic acid, mefenamic acid, sodium salicylate, choline salicylate, sasapyrine, clofezone, etodolac.

2. Antiulcer agents

- 20 Sulpiride, cetraxate hydrochloride, gefarnate, irsogladine maleate, cimetidine, unitidine hydrochloride, famotidine, nizatidine, roxatidine acetate hydrochloride.

3. Coronary vasodilators

- Nifedipine, isosorbide dinitrate, diltiazem hydrochloride, trapidil, dipyridamole, dilazep dihydrochloride, methyl 2,6-dimethyl-4-(2-nitrophenyl)-5-(2-oxo-1,3,2-dioxaphosphorinan-2-yl)-1,4-dihydropyridine-3-carboxylate, verapamil, nicardipine, nicardipine hydrochloride, verapamil hydrochloride.

- 25 4. Peripheral vasodilators

Ifenprodil tartrate, cinepazide maleate, cyclandelate, cinnarizine, pentoxifylline.

5. Antibiotics

- Ampicillin, amoxicillin, cefalexin, erythromycin ethylsuccinate, bacampicillin hydrochloride, minocycline hydrochloride, chloramphenicol, tetracycline, erythromycin.

- 30 6. Synthetic antibacterial agents

Nalidixic acid, piromidic acid, pipemidic acid trihydrate, enoxacin, cinoxacin, ofloxacin, norfloxacin, ciprofloxacin hydrochloride, sulfamethoxazole trimethoprim, 6-fluoro-1-methyl-7-[4-(5-methyl-2-oxo-1,3-dioxolen-4-yl)methyl-1-piperaziny]-4-oxo-4H[1,3]thiazeto[3,2-a]quinoline-3-carboxylic acid.

7. Antispasmodics

- 35 Propantheline bromide, atropine sulfate, oxopium bromide, time-bidium bromide, butylscopolamine bromide, trospium chloride, butropium bromide, N-methylscopolamine methylsulfate, methyloctatropine bromide, butropium bromide.

9. Antitussive, anti-asthmatic agents

- 40 Theophylline, aminophylline, methylephedrine hydrochloride, procaterol hydrochloride, trimetoxinol hydrochloride, codeine phosphate, sodium cromoglicate, tranilast, dextromethorphan hydrobromide, dimemorfan phosphate, clobutanol hydrochloride, fominoben hydrochloride, benproperine phosphate, dimemorfan phosphate, tipecidine hibenazate, eprazinone hydrochloride, clofedanol hydrochloride, ephedrine hydrochloride, noscapine, calbetapentane citrate, oxeladin tannate, isoaminile citrate, eprazinone hydrochloride.

10. Bronchodilators

- 45 Diprophylline, salbutamol sulfate, clorprenaline hydrochloride, formoterol fumarate, orciprenaline sulfate, pirbuterol hydrochloride, hexoprenaline sulfate, bitolterol mesylate, clenbuterol hydrochloride, terbutaline sulfate, mabuterol hydrochloride, fenoterol hydrobromide, methoxyphenamine hydrochloride.

11. Diuretics

- 50 Furosemide, acetazolamide, trichlormethiazide, thyclothiazide, hydrochlorothiazide, hydroflumethiazide, ethiazide, cyclopenthiazide, spironolactone, triamterene, fluorothiazide, piretamide, mefrumide, ethacrynic acid, azosemide, clofenamide.

12. Muscle relaxants

- 55 Chlorphenesin carbamate, tolperisone hydrochloride, eperisone hydrochloride, tizanidine hydrochloride, mephenesin, chlorzoxazone, phenprobamate, methocarbamol, chlormezanone, pridinol mesylate, alfoqualone, baclofen, pridinol mesylate, dantrolene sodium.

13. Brain metabolism improvers

Meclofenoxate hydrochloride.

14. Minor tranquilizers

Oxazolam, diazepam, clonazepam, metazepam, temazepam, fludiazepam, meprobamate, nitrazepam, chlorthalidone.

15. Major tranquilizers

Sulpirid, clocapramine hydrochloride, sodepine, chlorpromazine, haloperidol.

16. β -blockers

Pindolol, propranolol hydrochloride, carteolol hydrochloride, metoprolol tartrate, labetalol hydrochloride, oxprenolol hydrochloride, acebutolol hydrochloride, buferolol hydrochloride, alprenolol hydrochloride, arotinolol hydrochloride, oxprenolol hydrochloride, nadolol, bucumolol hydrochloride, indenolol hydrochloride, timolol maleate, befunolol hydrochloride, carteolol hydrochloride, bupranolol hydrochloride.

17. Antiarrhythmic agents

Procainamide hydrochloride, disopyramide, ajmaline, quinidine sulfate, aprindine hydrochloride, propafenone hydrochloride, mexiletine hydrochloride.

18. Gout suppressants

Allopurinol, probenecid, colchicine, sulfinpyrazone, benzbromarone, bucolome.

19. Anticoagulants

Ticlopidine hydrochloride, dicumarol, fulfarin potassium.

20. Antiepileptic agents

Phenytoin, sodium valproate, metharbital, carbamazepine.

21. Antihistaminics

Chlorpheniramine maleate, cromastin fumarate, mequitazine, alimemazine tartrate, cycloheptazine hydrochloride.

22. Antiemetics Difenidol hydrochloride, metoclopramide, domperidone, betahistine mesylate, trimebutine maleate.

23. Hypotensives

Dimethylaminoethyl reserpilate dihydrochloride, rescinnamine, methyl dopa, prazosin hydrochloride, bunazosin hydrochloride, clonidine hydrochloride, budralazine, urapidin.

24. Sympathomimetic agents

Dihydroergotamine mesylate, isoproterenol hydrochloride, etilefrine hydrochloride.

25. Expectorants

Bromhexine hydrochloride, carbocysteine, ethyl cysteine hydrochloride, methyl cysteine hydrochloride.

26. Oral antidiabetic agents

Glibenclamide, tolbutamide, glymidine sodium.

27. Circulatory agents

Ubidecarenone, ATP-2Na.

28. Iron preparations

Ferrous sulfate, dried ferrous sulfate.

29. Vitamins

Vitamin B1, vitamin B2, vitamin B6, vitamin B12, vitamin C, folic acid.

30. Pollakiuria remedies

Flavoxate hydrochloride, oxybutynin hydrochloride, terodiline hydrochloride, 4-diethylamino-1,1-dimethyl-2-butynyl (\pm)- α -cyclohexyl- α -phenylglycolate hydrochloride monohydrate.

31. Angiotensin-converting enzyme inhibitors

Enalapril maleate, alacepril, delapril hydrochloride.

EFFECTS OF THE INVENTION

[0035] The fast soluble tablet relating to the present invention has the following effects:

(1) Offers improved compliance, including safe administration to the aged, children, infants and patients weak in swallowing ability.

(2) Free of the risk of suffocation due to a physical obstruction when swallowed, thus offering improved safety.

(3) Safely administrable to patients on water intake restriction.

(4) Easily portable and suitable for transportation by patients.

(5) Free of the need of weighing, an essential drawback in liquids etc.

(6) Drug retention at high concentrations in tablets allows application to drugs that must be administered at high doses.

(7) Can be industrially produced more simply, more efficiently and in larger amounts, in comparison with tableting based on freeze-drying.

BEST MODES FOR CARRYING OUT THE INVENTION

[0036] The present invention is hereinafter illustrated in more detail by means of the following examples.

5 Example 1

[0037] To 60 g of xylitol, 2 ml of purified water was added, followed by kneading in a mortar. 1 g of the kneaded mixture was subjected to compressive shaping at a compression force of 980 - 6860 N (100 - 700 kg) and a compression rate of 20 mm/min, using a material testing machine (Autograph (trade mark):AG-5000, produced by Shimadzu Corporation), to yield tablets of 13 mm diameter. The resulting tablets were dried at 50°C for 2 hours in a hot air circulation oven (GT-100, produced by Alp Corporation) to yield fast soluble tablets of the present invention.

Example 2

15 [0038] 48 g of xylitol and 12 g of lactose were uniformly mixed in a mortar, followed by kneading with 2 ml of purified water added. 1 g of the kneaded mixture was subjected to compressive shaping at a compression force of 980 - 6860 N (100 - 700 kg) and a compression rate of 20 mm/min, using a material testing machine (Autograph (trade mark):AG-5000, produced by Shimadzu Corporation), to yield tablets of 13 mm diameter. The resulting tablets were dried at 50 °C for 2 hours in a hot air circulation oven (GT-100, produced by Alp Corporation) to yield fast soluble tablets of the present invention.

Example 3

25 [0039] 48 g of xylitol and 12 g of mannitol were uniformly mixed in a mortar, followed by kneading with 2 ml of purified water added. 1 g of the kneaded mixture was subjected to compressive shaping at a compression force of 980 - 6860 N (100 - 700 kg) and a compression rate of 20 mm/min, using a material testing machine (Autograph (trade mark):AG-5000, produced by Shimadzu Corporation), to yield tablets of 13 mm diameter. The resulting tablets were dried at 50°C for 2 hours in a hot air circulation oven (GT-100, produced by Alp Corporation) to yield fast soluble tablets of the present invention.

Example 4

35 [0040] 60 g of mannitol was placed in a mortar and kneaded with 2 ml of purified water. 1 g of the kneaded mixture was subjected to compressive shaping at a compression force of 980 - 6860 N (100 - 700 kg) and a compression rate of 20 mm/min, using a material testing machine (Autograph (trade mark):AG-5000, produced by Shimadzu Corporation), to yield tablets of 13 mm diameter. The resulting tablets were dried at 50°C for 2 hours in a hot air circulation oven (GT-100, produced by Alp Corporation) to yield fast soluble tablets of the present invention.

Example 5

40 [0041] 308 g of xylitol, 77 g of mannitol, 12.5 g of diclofenac sodium and 2.5 g of polyvinylpyrrolidone were mixed in a kneader (KM-1.5, produced by Kikusui Seisakusho, Ltd.) for 10 minutes, followed by kneading with 12 ml of purified water added. The resulting mixture was applied to a feather mill (FM-1, produced by Hosokawa Micron Corp.) equipped with a screen of 12 mm pores, to uniformize particle size. The resulting granules were subjected to compressive shaping at a compression force of 1960 N (200 kg), using a tableting machine (Clean Press Correct 12HUK, produced by Kikusui Seisakusho, Ltd.) equipped with a forced mechanical stirrer, to yield tablets of 10.5 mm diameter weighing 800 mg each. The shaped tablets were then dried at 50°C for 3 hours in a hot air circulation oven (GT-100, produced by Alp Corporation) to yield fast soluble tablets of the present invention.

50 Example 6

[0042] 3 g of polyvinylpyrrolidone, 100 g of lactose and 3 g of oxybutynin hydrochloride were mixed in a micro-type through-vision mixer (W-8, produced by Tsutsui Rikagaku Kiki) for 8 minutes. 106 g of this mixture and 394 g of xylitol were mixed in a kneader (KM-1.5, produced by Kikusui Seisakusho, Ltd.) for 10 minutes, followed by kneading with 15 ml of purified water added. The resulting mixture was applied to a feather mill (FM-1, produced by Hosokawa Micron Corp.) equipped with a screen of 12 mm pores, to uniformize particle size. The resulting granules were subjected to compressive shaping at a compression force of 1470 N (150 kg), using a tableting machine (Clean Press Correct 12HUK, produced by Kikusui Seisakusho, Ltd.) equipped with a forced mechanical stirrer, to yield tablets of 9 mm

diameter weighing 500 mg each. The shaped tablets were then dried at 55°C for 3 hours in a hot air circulation oven (GT-100, produced by Alp Corporation) to yield fast soluble tablets of the present invention.

Example 7

5
[0043] 2.5 g of acacia powder, 146 g of mannitol and 10 g of nifedipine were mixed in a micro-type through-vision mixer (W-8, produced by Tsutsui Rikagaku Kiki) for 8 minutes. 158.5 g of this mixture and 341.5 g of xylitol were mixed in a kneader (KM-1.5, produced by Kikusui Seisakusho, Ltd.) for 10 minutes, followed by kneading with 14 ml of purified water added. The resulting mixture was applied to a feather mill (FM-1, produced by Hosokawa Micron Corp.) equipped with a screen of 12 mm pores, to uniformize particle size. The resulting granules were subjected to compressive shaping at a compression force of 2156 N (220 kg), using a rotary tableting machine (RT-F-9, produced by Kikusui Seisakusho, Ltd.), to yield tablets of 15 mm diameter weighing 1,000 mg each. The shaped tablets were then dried at 55°C for 3 hours in a hot air circulation oven (GT-100, produced by Alp Corporation) to yield fast soluble tablets of the present invention.

Example 8

15
[0044] 1.5 g of polyvinylpyrrolidone, 412.5 g of xylitol, 111 g of lactose and 125 g of cefalexin were mixed in a kneader (KM-1.5, produced by Kikusui Seisakusho, Ltd.) for 10 minutes, followed by kneading with 20 ml of purified water added. The resulting mixture was applied to a feather mill (FM-1, produced by Hosokawa Micron Corp.) equipped with a screen of 12 mm pores, to uniformize particle size. The resulting granules were subjected to compressive shaping at a compression force of 1764 N (180 kg), using a rotary tableting machine (RT-F-9, produced by Kikusui Seisakusho, Ltd.), to yield tablets of 15 mm diameter weighing 1,300 mg each. The shaped tablets were then dried at 55°C for 3 hours in a hot air circulation oven (GT-100, produced by Alp Corporation) to yield fast soluble tablets of the present invention.

Comparative Example 1

25
[0045] 300 g of xylitol was passed through a 32-mesh sieve. 1 g of the powder was subjected to compressive shaping at a compression force of 490 - 9800 N (50 - 1,000 kg) and a compression rate of 20 mm/min, using a material testing machine (Autograph (trade mark):AG-5000, produced by Shimadzu Corporation), to yield tablets of 13 mm diameter for comparative testing.

Comparative Example 2

35
[0046] 300 g of mannitol was passed through a 32-mesh sieve. 1 g of the powder was subjected to compressive shaping at a compression force of 980 - 6860 N (100 - 700 kg) and a compression rate of 20 mm/min, using a material testing machine (Autograph (trade mark):AG-5000, produced by Shimadzu Corporation), to yield tablets of 13 mm diameter for comparative testing.

Test Example 1

40
[0047] For the inventive fast soluble tablets of Example 1, the tablets of Comparative Example 1, and the undried tablets of Example 1, tensile strength and oral cavity dissolution time were measured. Tensile strength was measured using a material testing machine (Autograph (trade mark):AG-5000, produced by Shimadzu Corporation) equipped with a 100 KGF load cell, at a compression rate of 20 mm/min, with a full scale of 10 - 20 KGF. The point at which the load reduction rate for 1 second lower to 50% of the full scale was taken as the breaking point. On the basis of breaking point data, the tensile strength of each tablet preparation was calculated as the mean of 5 tablets using the following equation:

$$\tau = 2P / \pi DT$$

50
 τ : Tensile strength $9.8 \times 10^4 \text{ Pa (kg/cm}^2\text{)}$

55 P: Hardness (kg)

D: Tablet diameter (cm)

T: Tablet thickness (cm)

[0048] Oral cavity dissolution time was measured as the mean of 5 subjects. Each tablet was kept unbitten in the mouth, and the time to tablet mass dissolution and disappearance was measured. The results are given in Figure 1. From Figure 1, it is seen that the fast soluble tablet produced by the process of the present invention had excellent properties for a fast soluble tablet, having a tensile strength exceeding 29.4×10^4 Pa (3 kg/cm²) and an oral cavity dissolution time within 30 second when it was prepared under a compression force of 50 - 300 kg. As for the undried tablets and the tablets obtained by dry tableting, tensile strength was lower than 29.4×10^4 Pa (3 kg/cm²) when they were prepared under a compression force of 50 - 1,000 kg; they were not practically applicable.

Test Example 2

[0049] For the inventive fast soluble tablets of Example 2, tensile strength and oral cavity dissolution time were measured in the same manner as in Test Example 1. The results are given in Figure 2.

[0050] From Figure 2, it is seen that the fast soluble tablet of the present invention has excellent properties for a fast soluble tablet, having a tensile strength exceeding 78.4×10^4 Pa (8 kg/cm²) and an oral cavity dissolution time within 1 minute over the range of compression forces measured.

Test Example 3

[0051] For the inventive fast soluble tablets of Example 3, tensile strength and oral cavity dissolution time were measured in the same manner as in Test Example 1. The results are given in Figure 3.

[0052] From Figure 3, it is seen that the fast soluble tablet of the present invention had excellent properties for a fast soluble tablet, having a tensile strength exceeding 68.6×10^4 Pa (7 kg/cm²) and an oral cavity dissolution time within 40 seconds over the range of compression forces measured.

Test Example 4

[0053] For the fast soluble tablets of Example 4, the tablets of Comparative Example 2 and the undried tablets of Example 4, tensile strength and oral cavity dissolution time were measured in the same manner as in Test Example 1. The results are given in Figure 4.

From Figure 4, it is seen that the fast soluble tablet produced by the process of the present invention were practically applicable, having much higher tensile strength, in comparison with the undried tablets and the tablets obtained by dry tableting.

Test Example 5

[0054] For the inventive fast soluble tablets of Examples 5 through 8, tensile strength, oral cavity dissolution time, disintegration time and degree of wear were measured. Tensile strength and oral cavity dissolution time were measured in the same manner as in Test Example 1. Disintegration time was measured by the method using water specified in the Pharmacopoeia of Japan. Friability was measured on one tablet for each preparation, using a friabilator. The results are given in Table 1.

Table 1

	Example 5	Example 6	Example 7	Example 8
Tensile strength Pa (kg/cm ²)	89.18×10^4 (9.1)	73.5×10^4 (7.5)	119.56×10^4 (12.2)	83.3×10^4 (8.5)
Dissolution time (in oral cavity, seconds)	15	15	18	25
Disintegration time (seconds)	12	12	15	20
Friability (%) (in 3 minutes)	0.3	0.1	0.2	0.3

Table 1 (continued)

	Example 5	Example 6	Example 7	Example 8
Remarks	*Good appearance *Dissolved rapidly in the oral cavity. *Easily swallowable.	*Good appearance *Dissolved rapidly in the oral cavity. *Easily swallowable.	*Good appearance *Dissolved rapidly in the oral cavity. *Easily swallowable.	*Good appearance *Dissolved rapidly in the oral cavity. *Easily swallowable.

[0055] From Table 1, it is seen that the fast soluble tablets of the present invention had excellent properties for a fast soluble tablet, having a tensile strength exceeding 68.6×10^4 Pa (7 kg/cm²) and an oral cavity dissolution time within 30 seconds.

BRIEF DESCRIPTION OF THE DRAWINGS

[0056] Figure 1 shows the relations between tensile strength, and oral cavity dissolution time and compression force for each of the fast soluble tablets of Example 1, the tablets of Comparative Example 1, and the undried tablets of Example 1.

[0057] The abscissa indicates compression force; the left ordinate indicates tensile strength (Pa); the right ordinate indicates oral cavity dissolution time (min).

[0058] In Figure, the symbols denote the following:

- : Tensile strength of the inventive fast soluble tablets of Example 1
- : Oral cavity dissolution time of the inventive fast soluble tablets of Example 1
- ▲: Tensile strength of the undried tablets of Example 1
- : Tensile strength of the tablets of Comparative Example 1

[0059] Figure 2 shows the relations between tensile strength, and oral cavity dissolution time and compression force for the inventive fast soluble tablets of Example 2.

[0060] The abscissa indicates compression force; the left ordinate indicates tensile strength (Pa); the right ordinate indicates oral cavity dissolution time (min).

[0061] In Figure, the symbols denote the following:

- : Tensile strength of the inventive fast soluble tablets of Example 2
- : Oral cavity dissolution time of the inventive fast soluble tablets of Example 2

[0062] Figure 3 shows the relations between tensile strength, and oral cavity dissolution time and compression force for the inventive fast soluble tablets of Example 3.

[0063] The abscissa indicates compression force; the left ordinate indicates tensile strength (Pa); the right ordinate indicates oral cavity dissolution time (min).

[0064] In Figure, the symbols denote the following:

- : Tensile strength of the inventive fast soluble tablets of Example 3
- : Oral cavity dissolution time of the inventive fast soluble tablets of Example 3

[0065] Figure 4 shows the relations between tensile strength, and oral cavity dissolution time and compression force for each of the fast soluble tablets of Example 4, the tablets of Comparative Example 2 and the undried tablets of Example 4.

[0066] The abscissa indicates compression force; the left ordinate indicates tensile strength (Pa); the right ordinate indicates oral cavity dissolution time (min).

[0067] In Figure, the symbols denote the following:

- : Tensile strength of the inventive fast soluble tablets of Example 4
- : Oral cavity dissolution time of the inventive fast soluble tablets of Example 4
- ▲: Tensile strength of the undried tablets of Example 4
- : Tensile strength of the tablets of Comparative Example 2

Claims

1. A process for the production of pharmaceutical tablets which rapidly dissolve in the oral cavity having a pharmaceutically active ingredient (drug) and an excipient, comprising wet granulating the drug and an excipient which is readily soluble in water, compressing the wet granulate into tablet form and drying the compressed tablet.
2. A process according to claim 1, wherein the excipient is a sugar alcohol or a sugar.
3. A process according to claim 2, wherein the sugar alcohol is xylitol.
4. A process according to claim 3, wherein the tablet is prepared at 480 - 2940 N (50-300 Kg) of the compressive shaping pressure.
5. A process according to claim 1, wherein the excipient is a mixture of xylitol and lactose.
6. A process according to claim 1, wherein the excipient is a mixture of xylitol and mannitol.
7. A pharmaceutical tablet which rapidly dissolves in the oral cavity obtainable by the process as defined in claim 1, having a pharmaceutically active ingredient (drug), and the mixture of xylitol and at least one member selected from the group consisting of lactose and mannitol.

Patentansprüche

1. Verfahren für die Herstellung von pharmazeutischen Tabletten, die sich schnell in der Mundhöhle lösen, die einen pharmazeutisch aktiven Bestandteil (Arzneimittel) und einen Träger haben, umfassend Feuchtgranulieren des Arzneimittels und Trägers, der leicht in Wasser löslich ist, Komprimieren des Feuchtgranulats in Tablettenform und Trocknen der komprimierten Tablette.
2. Verfahren nach Anspruch 1, wobei der Träger ein Zuckeralkohol oder ein Zucker ist.
3. Verfahren nach Anspruch 2, wobei der Zuckeralkohol Xylitol ist.
4. Verfahren nach Anspruch 3, wobei die Tablette bei 480 -2940 N (50-300 kg) des Kompressionsformdrucks hergestellt wird.
5. Verfahren nach Anspruch 1, wobei der Träger eine Mischung von Xylitol und Lactose ist.
6. Verfahren nach Anspruch 1, wobei der Träger eine Mischung aus Xylitol und Manitol ist.
7. Pharmazeutische Tablette, die sich schnell in der Mundhöhle löst, erhältlich durch das Verfahren, wie in Anspruch 1 definiert, die einen pharmazeutisch aktiven Bestandteil (Arzneimittel) und die Mischung aus Xylitol und mindestens einem Glied, ausgewählt aus der Gruppe, bestehend aus Lactose und Manitol, hat.

Revendications

1. Procédé pour la fabrication de cachets pharmaceutiques qui se dissolvent rapidement dans la cavité buccale contenant un ingrédient pharmaceutiquement actif (médicament) et un excipient, comprenant la granulation par voie humide du médicament et d'un excipient qui est facilement soluble dans l'eau, la compression des granulés humides sous la forme de cachets et le séchage des cachets comprimés.
2. Procédé suivant la revendication 1, dans lequel l'excipient est un alcool de sucre ou un sucre.
3. Procédé suivant la revendication 2, dans lequel l'alcool de sucre est du xylitol.
4. Procédé suivant la revendication 3, dans lequel les cachets sont préparés à 480-2940 N (50-300 kg) de pression de façonnage par compression.

EP 0 627 218 B1

5. Procédé suivant la revendication 1, dans lequel l'excipient est un mélange de xylitol et de lactose.
6. Procédé suivant la revendication 1, dans lequel l'excipient est un mélange de xylitol et de mannitol.
- 5 7. Cachet pharmaceutique qui se dissout rapidement dans la cavité buccale pouvant être obtenu par le procédé suivant la revendication 1, contenant un ingrédient pharmaceutiquement actif (médicament) et le mélange de xylitol et d'au moins un élément choisi dans le groupe constitué de lactose et de mannitol.

10

15

20

25

30

35

40

45

50

55




Fig. 1




Fig. 2




Fig. 3




Fig. 4